Selexipag是首款选择性口服前列环素IP受体激动剂,由Actelion公司研发,2015年12月21日获得美国FDA批准上市,商品名为Uptravi。该药最初由日本新药株式会社发现并合成,用于肺动脉高压(PAH)的治疗[1]。selexipag的中文化学名称为:2-{4-[(5,6-二苯基吡嗪-2-基)(异丙基)氨基]丁氧基}-N(甲磺酰基)乙酰胺;英文 Selexipag is the first selective oral prostacyclin IP receptor agonist developed by Actelion and approved by the U.S. FDA on December 21, 2015 under the tradename Uptravi. The drug was originally discovered by Japan’s New Drug Co., Ltd. and synthesized for the treatment of pulmonary hypertension (PAH) [1]. The Chinese chemical name of selexipag is: 2- {4 - [(5,6-diphenylpyrazin-2- yl) (isopropyl) amino] butoxy} -N (methylsulfonyl) acetamide;